AIM2 and lung cancer: Additionally, a recent study demonstrated that in a LAC mouse model, AIM2-deficient mice were able to mitigate KRAS-driven LUAD by facilitating the release of mature caspase-1 and IL-1β, thereby inhibiting the growth of lung cancer cells in an inflammasome adapter-independent manner59.